CDR2L Is the Major Yo Antibody Target in Paraneoplastic Cerebellar Degeneration.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31148214.
- Also identified by DOI 10.1002/ana.25511.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The pathogenesis of Yo-mediated paraneoplastic cerebellar degeneration (PCD) is unclear. We applied cerebrospinal fluid and serum from PCD patients as well as CDR2 and CDR2L antibodies to neuronal tissue, cancer cell lines, and cells transfected with recombinant CDR2 and CDR2L to elucidate which is the major antigen of Yo antibodies. We found that Yo antibodies bound endogenous CDR2L, but not endogenous CDR2. However, Yo antibodies can bind the recombinant CDR2 protein used in routine clinical testing for these antibodies. Because Yo antibodies only bind endogenous CDR2L, we conclude that CDR2L is the major antigen of Yo antibodies in PCD. ANN NEUROL 2019;86:316-321.
Medical subject headings
- Autoantibodies
- Autoantigens
- Cerebellum
- Nerve Tissue Proteins
- Paraneoplastic Cerebellar Degeneration